Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Results Among the 19 097 participants (mean [SD] age, 69.1 [9.8] years; 10 148 women [53.1%]) included, 10 139 (53.1%) underwent an amyloid PET scan and 8958 (46.9%) had an amyloid CSF measurement. Conclusions and relevance This study found that CSF-based estimates using adjusted data-driven cutoffs were up to 10% higher than PET-based estimates in people without dementia, whereas the results were similar among people with dementia. This finding suggests that preclinical and prodromal AD may be more prevalent than previously estimated, which has important implications for clinical trial recruitment strategies and health care planning policies.

What this study adds

Evidence grade: Moderate

This is a cross-sectional study of 97 participants. CSF-based estimates of amyloid abnormality were up to 10% higher than PET-based estimates in people without dementia, suggesting preclinical and prodromal Alzheimer's disease may be more common than previously estimated. Reported effect size: 53.1%; 46.9%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., et al. (2022). Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA neurology. https://doi.org/10.1001/jamaneurol.2021.5216

Vancouver

Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, et al. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA neurology. 2022. doi:10.1001/jamaneurol.2021.5216. PMID: 35099509.

BibTeX

@article{jansen2022-35099509,
  author  = {Jansen, W. J. and Janssen, O. and Tijms, B. M. and Vos, S. J. B. and Ossenkoppele, R. and Visser, P. J. and {Amyloid Biomarker Study Group} and Aarsland, D. and others},
  title   = {{Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2021.5216},
  pmid    = {35099509},
  url     = {https://doi.org/10.1001/jamaneurol.2021.5216}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

CSF-based estimates of amyloid abnormality were up to 10% higher than PET-based estimates in people without dementia, suggesting preclinical and prodromal Alzheimer's disease may be more common than previously estimated. This affects trial recruitment and health care planning, not treatment or cure.

Study details

How this study scored 70/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 4 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 1 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 4 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 70 of 100.70 of 100 points earned30 not earned

Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record 2 / 4 JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 1 / 4 97 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 292 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 48.7 citations a year over 6 year(s) since 2022
Impact for its field and year 5 / 6 Cited 34.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 30 other studies in this library
Still being cited 4 / 4 Cited 204 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Jan O. Marcusson: h-index 51 (OpenAlex, whole career)
Institution's track record 3 / 3 Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 124 institution(s) in 24 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 35099509)
Free to read 0 / 2 Behind a paywall — scores zero
Total 70 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.

Later studies that cite this one

30 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Biomarkers from nearby years

Also in Biomarkers

138 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.

Similar studies

More on Biomarkers

See all studies in Biomarkers →